Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2011134899) COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A MTOR INHIBITOR
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2011/134899 International Application No.: PCT/EP2011/056461
Publication Date: 03.11.2011 International Filing Date: 21.04.2011
IPC:
A61K 39/395 (2006.01) ,A61K 31/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
Applicants:
HERTING, Frank [DE/DE]; DE (UsOnly)
KLEIN, Christian [DE/CH]; CH (UsOnly)
ROCHE GLYCART AG [CH/CH]; Wagistrasse 18 CH-8952 Schlieren, CH (AllExceptUS)
Inventors:
HERTING, Frank; DE
KLEIN, Christian; CH
Agent:
JENNI, Wolfgang; Roche Diagnostics GmbH Patent Department (LPP.....6164) P.O.Box 11 52 82372 Penzberg, DE
Priority Data:
10161181.227.04.2010EP
Title (EN) COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A MTOR INHIBITOR
(FR) POLYTHÉRAPIE D'UN ANTICORPS ANTI-CD20 AFUCOSYLÉ ET D'UN INHIBITEUR DE MTOR
Abstract:
(EN) The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a m TOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.
(FR) La présente invention concerne la polythérapie d'un anticorps anti-CD20 afucosylé et d'un inhibiteur de mTOR pour le traitement du cancer, notamment la polythérapie de cancers exprimant CD20 par un anticorps B-Ly1 humanisé afucosylé et par un inhibiteur de mTOR tel que Temsirolimus ou Everolimus.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)